Bristol-Myers Squibb (BMY) received approval from the US Food and Drug Administration for nivolumab with ipilimumab to treat a colorectal cancer type in patients 12 years or older, the regulator said Tuesday.
The combination was tested in a randomized, three-arm, open-label trial in immunotherapy-naive patients with unresectable or metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer.
The FDA also converted the accelerated approval to regular approval for single agent nivolumab for patients 12 years or older with the disease, that has progressed following fluoropyrimidine, oxaliplatin, and irinotecan.
Price: 53.37, Change: -1.82, Percent Change: -3.30
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。